糖尿病性黄斑水肿
指南
医学
养生
重症监护医学
血管内皮生长因子
黄斑水肿
糖尿病
眼科
糖尿病性视网膜病变
血管内皮生长因子受体
外科
内科学
视力
病理
内分泌学
标识
DOI:10.3760/cma.j.issn.2095-0160.2016.12.002
摘要
Diabetic macular edema (DME) is the most common reason for visual impairment in diabetic eye diseases.DME is easy to relapse and the treatment outcome is beyond satisfied.Anti-vascular endothelial growth factor (anti-VEGF) therapy has been proposed to be a first-line or key treatment regimen in the management guideline for DME.However, in clinical practice, there still are many ambiguous and controversial views in the choice and implement of different managing paradigms, including the therapeutical goal, the assessment of treatment effectiveness, the explanation of the guidelines, the regimen of anti-VEGF therapy, the value evaluation of laser photocoagulation, the use of steroids and the management of recurrent DME.Recently, the researches of treating drugs for DME are developing and making a great progress, so eye doctors should track the research results, improve the therapeutical regimen, fully understand the advantages and disadvantages of different treating methods and standardize the treatment process in order to release the best treatment effects on DME.
Key words:
Diabetes mellitus/complications; Macular edema/therapeutical effects; Guideline; Vascular endothelial growth factor; Laser/therapy use; Management regimen
科研通智能强力驱动
Strongly Powered by AbleSci AI